HBOT and Wound Healing

HBOT and Wound Healing

How can HBOT heal wounds?

Hyperbaric Oxygen Therapy (HBOT) is a medical treatment that involves breathing  oxygen in a hyperbaric chamber, where the pressure is increased to greater than atmospheric pressure. HBOT has been shown to have therapeutic benefits for various medical conditions, including wound healing.

Wound healing is a complex process that involves a series of cellular and molecular events. The process can be divided into three overlapping phases: 

InflammationProliferationand Remodelling. 

Inflammation is the initial response to tissue injury and involves the recruitment of immune cells to the site of the injury. Proliferation is the phase in which new tissue is formed, and remodeling is the phase in which the new tissue is remodeled and strengthened.


HBOT enhance all three phases of wound healing

HBOT has been found to enhance all three phases of the wound healing process. The therapy increases the amount of oxygen in the blood and tissues, which enhances the body's ability to heal itself. Oxygen is essential for the production of energy and helps to repair damaged tissues. Additionally, oxygen helps to stimulate the production of new blood vessels, which improves circulation and promotes tissue regeneration.

In the inflammation phase, HBOT has been found to reduce inflammation and oxidative stress. Inflammation is a natural response of the body to injury, but chronic inflammation can delay the healing process. HBOT has been shown to reduce the expression of pro-inflammatory cytokines, such as interleukin-1β, interleukin-6, and tumor necrosis factor-alpha, while increasing the expression of anti-inflammatory cytokines, such as interleukin-10. Anti-inflammatory cytokines help to suppress the immune response and reduce inflammation.

In the proliferation phase, HBOT has been found to promote angiogenesis and tissue regeneration. Angiogenesis is the formation of new blood vessels, which is essential for the delivery of oxygen and nutrients to the healing tissue. HBOT has been found to stimulate the production of vascular endothelial growth factor (VEGF), a protein that plays a crucial role in the formation of new blood vessels. VEGF promotes the growth of endothelial cells, which line the inside of blood vessels. Endothelial cells then form new blood vessels by sprouting from existing ones, a process known as angiogenesis. HBOT has also been found to promote the proliferation of fibroblasts, which are cells that produce collagen and other extracellular matrix proteins. Collagen is essential for the strength and stability of the healing tissue.

In the remodeling phase, HBOT has been found to enhance collagen synthesis and remodeling. Collagen is the main component of the extracellular matrix, which provides structural support for the healing tissue. HBOT has been shown to increase the expression of genes associated with collagen synthesis and remodeling, such as collagen type I and matrix metalloproteinases (MMPs). MMPs are enzymes that degrade the extracellular matrix and help to remodel the tissue.

Several studies have investigated the effects of HBOT on wound healing. For example, a study published in the journal Advances in Skin & Wound Care found that HBOT improved wound healing in patients with diabetic foot ulcers. The study showed that HBOT increased the rate of wound closure and reduced the need for amputation. Similarly, another study published in the journal Wound Repair and Regeneration found that HBOT improved wound healing in patients with pressure ulcers. The study showed that HBOT increased the production of collagen and improved the strength of the healing tissue.

In conclusion, HBOT has been shown to enhance all three phases of the wound healing process by reducing inflammation, promoting angiogenesis and tissue regeneration, and enhancing collagen synthesis and remodeling. The therapy may be a promising option for the treatment of various medical conditions that involve tissue damage and impaired wound healing, such as diabetic foot ulcers and pressure ulcers. However, further research is needed to investigate the full therapeutic potential of HBOT for wound healing.

 

References:

  1. Thom SR. Hyperbaric oxygen: its mechanisms and efficacy. Plast Reconstr Surg. 2011;127 Suppl 1:131S-141S.

  2. Chen Y, et al. Hyperbaric oxygenation therapy promotes wound-healing in a murine model of hindlimb ischemia by suppressing inflammation and oxidative stress. J Trauma Acute Care Surg. 2018;84(1):142-151.

  3. Xu H, et al. Hyperbaric oxygen therapy suppresses NLRP3 inflammasome/caspase-1/IL-1β pathways in a rat model of multiple sclerosis. Brain Res. 2015;1627:12-20.

  4. Xu L, et al. Hyperbaric oxygen therapy ameliorates inflammation and oxidative stress in a rat model of Crohn's disease. Med Gas Res. 2019;9(4):190-196.

  5. Lu X, et al. Hyperbaric oxygen therapy for type 2 diabetes mellitus: a randomized, controlled clinical trial. J Inflamm Res. 2019;12:107-116.

  6. Zhang R, et al. Hyperbaric oxygen therapy enhances the mobilization of bone marrow stem cells in rats with myocardial infarction. Cardiology. 2009;114(3):173-182.

  7. Li Y, et al. Hyperbaric oxygenation treatment promotes osteogenic differentiation of bone marrow stromal cells in vitro. Stem Cell Res Ther. 2018;9(1):274.

  8. Yang Y, et al. Hyperbaric oxygen preconditioning enhances the efficacy of mesenchymal stem cells in a rat model of acute myocardial infarction. Exp Ther Med. 2018;16(1):385-393.

  9. Wang L, et al. Hyperbaric oxygen promotes neural stem cell proliferation and differentiation in vitro. Stem Cell Res Ther. 2018;9(1):268.

  10. Zhang Y, et al. Hyperbaric oxygen therapy promotes angiogenesis in a rat model of hindlimb ischemia by upregulating VEGF. Biomed Res Int. 2015;2015:925428.

  11. Zhou Z, et al. Hyperbaric oxygen therapy enhances the expression of genes associated with angiogenesis and inflammation in patients with peripheral arterial disease. Med Gas Res. 2018;8(3):101-106.

  12. Zhang H, et al. Hyperbaric oxygen therapy improves the quality of life of patients with diabetes and chronic foot ulcers: a prospective randomized controlled clinical trial. Ostomy Wound Manage. 2020;66(3):16-25.

Previous post Next post

View our HBOT Chambers